|
Endothelin antagonist sitaxentan good for CKD with heart disease. |
 |
 |
|
Science Daily: Placebo and nifedipine did not affect three markers of heart-related problems: blood levels of uric acid; blood levels of asymmetric dimethylarginine (ADMA), a blocker of NO production; and urine levels of endothelin-1. Sitaxentan treatment led to statistically significant reductions in all three of these markers. Sitaxentan reduced proteinuria (an excess excretion of protein in the urine) to a significantly greater extent than nifedipine. Proteinuria is an indicator of kidney dysfunction. Nifedpine and sitaxentan both reduced blood pressure to a similar extent.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
